Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Hepatocellular Carcinoma | Review

Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways

Authors: Jafar Ai, Neda Ketabchi, Javad Verdi, Nematollah Gheibi, Hossein Khadem Haghighian, Maria Kavianpour

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent type of malignant liver disease worldwide. Molecular changes in HCC collectively contribute to Wnt/β-catenin, as a tumor proliferative signaling pathway, toll-like receptors (TLRs), nuclear factor-kappa B (NF-κB), as well as the c-Jun NH2-terminal kinase (JNK), predominant signaling pathways linked to the release of tumor-promoting cytokines. It should also be noted that the Hippo signaling pathway plays an important role in organ size control, particularly in promoting tumorigenesis and HCC development. Nowadays, mesenchymal stromal cells (MSCs)-based therapies have been the subject of in vitro, in vivo, and clinical studies for liver such as cirrhosis, liver failure, and HCC. At present, despite the importance of basic molecular pathways of malignancies, limited information has been obtained on this background. Therefore, it can be difficult to determine the true concept of interactions between MSCs and tumor cells. What is known, these cells could migrate toward tumor sites so apply effects via paracrine interaction on HCC cells. For example, one of the inhibitory effects of MSCs is the overexpression of dickkopf-related protein 1 (DKK-1) as an important antagonist of the Wnt signaling pathway. A growing body of research challenging the therapeutic roles of MSCs through the secretion of various trophic factors in HCC. This review illustrates the complex behavior of MSCs and precisely how their inhibitory signals interface with HCC tumor cells.
Literature
1.
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81.PubMedCrossRef
2.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.PubMedCrossRef
3.
Janevska D, Chaloska-Ivanova V, Janevski VJ. Hepatocellular carcinoma: risk factors, diagnosis and treatment. Open Access Maced J Med Sci. 2015;3(4):732.PubMedPubMedCentralCrossRef
4.
Serhal R, Saliba N, Hilal G, Moussa M, Hassan GS, El Atat O, et al. Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: in vitro inhibition of carcinogenesis. World J Gastroenterol. 2019;25(5):567.PubMedPubMedCentralCrossRef
5.
Crissien AM, Frenette CJG. Current management of hepatocellular carcinoma. Hepatology. 2014;10(3):153.
6.
El-Ansary M, Abdel-Aziz I, Mogawer S, Abdel-Hamid S, Hammam O, Teaema S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev Rep. 2012;8(3):972–81.PubMedCrossRef
7.
Moradian Tehrani R, Verdi J, Noureddini M, Salehi R, Salarinia R, Mosalaei M, et al. Mesenchymal stem cells: a new platform for targeting suicide genes in cancer. J Cell Physiol. 2018;233(5):3831–45.PubMedCrossRef
8.
Elahi KC, Klein G, Avci-Adali M, Sievert KD, MacNeil S, Aicher WK. Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem cells Int. 2016;2016:5646384.PubMedCrossRef
9.
10.
11.
Hou L, Wang X, Zhou Y, Ma H, Wang Z, He J, et al. Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells. Tumor Biol. 2014;35(2):1239–50.CrossRef
12.
13.
Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, et al. AKT and N-Ras co-activation in the mouse liver promotes rapid carcinogenesis via mTORC1, FOXM1/SKP2, and c-Myc pathways. Hepatology (Baltimore, MD). 2012;55(3):833.CrossRef
14.
Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22(2):823.PubMedPubMedCentralCrossRef
15.
Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, et al. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res. 2014;34(4):1709–13.PubMedPubMedCentral
16.
Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 2006;203(5):1235–47.PubMedPubMedCentralCrossRef
17.
Hajighasemlou S, Pakzad S, Ai J, Muhammadnejad S, Mirmoghtadaei M, Hosseinzadeh F, et al. Characterization and validation of hepatocellular carcinoma (HCC) xenograft tumor as a suitable liver cancer model for preclinical mesenchymal stem cell studies. Asian Pac J Cancer Prev. 2018;19(6):1627–31.PubMedPubMedCentral
18.
Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Research. 2016;5:879.CrossRef
19.
Wands JR, Kim M. WNT/β-catenin signaling and hepatocellular carcinoma. Hepatology. 2014;60(2):452–4.PubMedCrossRef
20.
21.
22.
Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, Sancho E, et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol Cell Biol. 2006;26(22):8418–26.PubMedPubMedCentralCrossRef
23.
Byun T, Karimi M, Marsh J, Milovanovic T, Lin F, Holcombe R. Expression of secreted Wnt antagonists in gastrointestinal tissues: potential role in stem cell homeostasis. J Clin Pathol. 2005;58(5):515–9.PubMedPubMedCentralCrossRef
24.
Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills W, Benbrook D, et al. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 2012;31(22):2725.PubMedCrossRef
25.
Qiao L, Xu Z, Zhao T, Ye L, Zhang X. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008;269(1):67–77.PubMedCrossRef
26.
27.
Flores I, Blasco MA. The role of telomeres and telomerase in stem cell aging. FEBS Lett. 2010;584(17):3826–30.PubMedCrossRef
28.
Ozturk MB, Li Y, Tergaonkar V. Current insights to regulation and role of telomerase in human diseases. Antioxidants. 2017;6(1):17.PubMedCentralCrossRef
29.
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.PubMedCrossRef
30.
Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt–β-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67(22):10831–9.PubMedCrossRef
31.
Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology. 2004;127(4):1110–22.PubMedCrossRef
32.
Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002;8(2):450–6.PubMed
33.
Dahmani R, Just P-A, Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35(11):709–13.PubMedCrossRef
34.
Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61(1):S79–90.PubMedPubMedCentralCrossRef
35.
Rapisarda V, Loreto C, Malaguarnera M, Ardiri A, Proiti M, Rigano G, et al. Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol. 2016;8(13):573.PubMedPubMedCentralCrossRef
36.
Maeda S. NF-κB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract. 2010;2010:286–97.CrossRef
37.
38.
Sun B, Karin M. NF-κB signaling, liver disease and hepatoprotective agents. Oncogene. 2008;27(48):6228.PubMedCrossRef
39.
Yen C-J, Lin Y-J, Yen C-S, Tsai H-W, Tsai T-F, Chang K-Y, et al. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS ONE. 2012;7(7):e41931.PubMedPubMedCentralCrossRef
40.
Ippagunta SK, Pollock JA, Sharma N, Lin W, Chen T, Tawaratsumida K, et al. Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins. Sci Signal. 2018;11(543):eaaq1077.PubMedCrossRefPubMedCentral
41.
Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis. 2015;20(2):196–209.PubMedCrossRef
42.
Botos I, Segal DM, Davies DRJS. The structural biology of Toll-like receptors. J Anim Sci Technol. 2011;19(4):447–59.
43.
Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018;2018:1–12.
44.
Vollmer S, Strickson S, Zhang T, Gray N, Lee K, Rao V, et al. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists. Biochem J. 2017;2017:0097.
45.
Dunne A, Carpenter S, Brikos C, Gray P, Strelow A, Wesche H, et al. IRAK1 and IRAK4 promote phosphorylation, ubiquitination and degradation of MyD88 adapter-like (MAL). J Biol Chem. 2010;109:098137.
46.
Israël A. The IKK complex, a central regulator of NF-κB activation. Cold Spring Harbor Persp Biol. 2010;2(3):a000158.
47.
Suslov A, Boldanova T, Wang X, Wieland S, Heim MH. Hepatitis B virus does not interfere with innate immune responses in the human liver. Gastroenterology. 2018;154(6):1778–90.PubMedCrossRef
48.
Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005;79(11):7269–72.PubMedPubMedCentralCrossRef
49.
Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007;45(1):102–10.PubMedCrossRef
50.
Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med. 2015;7(304):304ra142.PubMedCrossRef
51.
Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 2004;127(5):1513–24.PubMedCrossRef
52.
Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012;590(3):447–58.PubMedCrossRef
53.
Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med. 2007;13(11):1324.PubMedCrossRef
54.
Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015;11(3):1693–700.PubMedCrossRef
55.
Zhu T, Wenjuan T, Tan Z, Liu L. Effects of inhibited expression of IRF3 in LPS-stimulated Kupffer cells on the activation of signal transduction pathways. Chin J Microbiol Immunol. 2015;8:587–94.
56.
Yu L-X, Ling Y, Wang H-Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Prec Oncol. 2018;2(1):6.CrossRef
57.
Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48(1):322–35.PubMedCrossRef
58.
Trucco LD, Roselli E, Araya P, Nuñez NG, Mena HA, Bocco JL, et al. Downregulation of adaptor protein MyD88 compromises the angiogenic potential of B16 murine melanoma. PLoS ONE. 2017;12(6):e0179897.PubMedPubMedCentralCrossRef
59.
60.
Stein I, Bramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.PubMedCrossRef
61.
Luo J-L, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death—a new approach to cancer therapy. J Clin Investig. 2005;115(10):2625–32.PubMedCrossRefPubMedCentral
62.
Greten FR, Arkan MC, Bollrath J, Hsu L-C, Goode J, Miething C, et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell. 2007;130(5):918–31.PubMedPubMedCentralCrossRef
63.
64.
Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. BBA Gene Regul Mech. 2010;1799(10):775–87.
65.
66.
67.
68.
Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi J, et al. High expression levels of IKKα and IKKβ are necessary for the malignant properties of liver cancer. Int J Cancer. 2010;126(5):1263–74.PubMedCrossRef
69.
Qiao L, Zhao TJ, Wang FZ, Shan CL, Ye LH, Zhang XD. NF-κB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells 1. Acta Pharmacol Sin. 2008;29(3):333–40.PubMedCrossRef
70.
71.
Eaton GJ Jr. Apoptosis signal-regulating kinase 1 modulates endochondral bone formation and osteoarthritis progression. Philadelphia: Thomas Jefferson University; 2015.
72.
73.
Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012;143(2):307–20.PubMedCrossRef
74.
Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008;99(5):836–42.PubMedCrossRef
75.
Trierweiler C, Hockenjos B, Zatloukal K, Thimme R, Blum H, Wagner E, et al. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ. 2016;23(4):576.PubMedCrossRef
76.
Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, et al. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol. 2007;171(1):297–303.PubMedPubMedCentralCrossRef
77.
Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. BBA Mol Cell Res. 2007;1773(8):1161–76.
78.
Choi J, Corder NL, Koduru B, Wang Y. Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radical Biol Med. 2014;72:267–84.CrossRef
79.
80.
Suhail M, Abdel-Hafiz H, Ali A, Fatima K, Damanhouri GA, Azhar E, et al. Potential mechanisms of hepatitis B virus induced liver injury. WJG. 2014;20(35):12462.PubMedCrossRefPubMedCentral
81.
Chen F, Beezhold K, Castranova V. JNK1, a potential therapeutic target for hepatocellular carcinoma. BBA Rev Cancer. 2009;1796(2):242–51.
82.
Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52(4):594–604.PubMedCrossRef
83.
Min L, He B, Hui L, editors. Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in cancer biology. New York: Elsevier; 2011.
84.
Park GB, Choi Y, Kim YS, Lee H-K, Kim D, Hur DY. ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells. Int J Oncol. 2014;44(3):977–85.PubMedCrossRef
85.
86.
Arango-Rodriguez ML, Ezquer F, Ezquer M, Conget P. Could cancer and infection be adverse effects of mesenchymal stromal cell therapy? World J Stem Cells. 2015;7(2):408.PubMedPubMedCentralCrossRef
87.
Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B. Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol. 2018;6:18.PubMedPubMedCentralCrossRef
88.
Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14–20.PubMedCrossRef
89.
Lin L, Du L. The role of secreted factors in stem cells-mediated immune regulation. Cell Immunol. 2018;326:24–32.PubMedCrossRef
90.
Davis JR, Tapon NJD. Hippo signalling during development. Development. 2019;146(18):167106.CrossRef
91.
92.
93.
Johnson RL. Hippo signaling and epithelial cell plasticity in mammalian liver development, homeostasis, injury and disease. Sci China Life Sci. 2019;26:1–8.
94.
95.
Zheng T, Wang J, Jiang H, Liu LJ. Hippo signaling in oval cells and hepatocarcinogenesis. Cancer Lett. 2011;302(2):91–9.PubMedCrossRef
96.
Jie L, Fan W, Weiqi D, Yingqun Z, Ling X, Miao S, et al. The hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract. 2013;2013:187070.PubMedPubMedCentralCrossRef
97.
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61.PubMedPubMedCentralCrossRef
98.
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115(19):4576–85.PubMedCrossRef
99.
Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68(8):2592–8.PubMedCrossRef
100.
Xiao H, Jiang N, Zhou B, Liu Q, Du CJ. TAZ regulates cell proliferation and epithelial–mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 2015;106(2):151–9.PubMedPubMedCentralCrossRef
101.
102.
103.
104.
Yuan F, Zhou W, Zou C, Zhang Z, Hu H, Dai Z, et al. Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways. Mol Cell Biochem. 2010;343(1–2):155–62.PubMedCrossRef
105.
El Asmar MF, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Rashed LA, et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res. 2011;30(1):49.PubMedPubMedCentralCrossRef
106.
Zhang C-L, Huang T, Wu B-L, He W-X, Liu D. Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017;8(43):75756.PubMedPubMedCentral
107.
Gomes CMF. The dual role of mesenchymal stem cells in tumor progression. Stem Cell Res Therapy. 2013;4(2):42.CrossRef
108.
Ma Y, Hao X, Zhang S, Zhang J. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat. 2012;133(2):473–85.PubMedCrossRef
109.
Zhang Y, Wang J, Wu D, Li M, Zhao F, Ren M, et al. il-21-secreting hUcMscs combined with mir-200c inhibit tumor growth and metastasis via repression of Wnt/β-catenin signaling and epithelial–mesenchymal transition in epithelial ovarian cancer. OncoTargets Therapy. 2018;11:2037.PubMedCrossRefPubMedCentral
110.
Subramanian A, Shu-Uin G, Kae-Siang N, Gauthaman K, Biswas A, Choolani M, et al. Human umbilical cord wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J Cell Biochem. 2012;113(6):1886–95.PubMedCrossRef
111.
Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol. 2003;75(3):248–55.PubMedCrossRef
112.
Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, Bhattacharya J. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 2009;113(18):4197–205.PubMedPubMedCentralCrossRef
113.
Lu Y, Yuan Y, Wang X, Wei L, Chen Y, Cong C, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther. 2008;7(2):245–51.PubMedCrossRef
114.
Wang ML, Pan CM, Chiou SH, Chen WH, Chang HY, Lee OKS, et al. Oncostatin M modulates the mesenchymal–epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res. 2012;72(22):6051–64.PubMedCrossRef
115.
Ryu H, Oh J-E, Rhee K-J, Baik SK, Kim J, Kang SJ, et al. Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-β and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett. 2014;352(2):220–7.PubMedCrossRef
116.
Du J, Zhou L, Chen X, Yan S, Ke M, Lu X, et al. IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol. 2012;44(8):1305–14.PubMedCrossRef
117.
118.
Loebinger M, Sage E, Davies D. Janes SJBjoc. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. 2010;103(11):1692.
119.
Zhao D, Hou L, Pan M, Hua J, Wang Z, He J, et al. Inhibitory effect and mechanism of mesenchymal stem cells cultured in 3D system on hepatoma cells HepG2. Appl Biochem Biotechnol. 2018;184(1):212–27.PubMedCrossRef
120.
Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96(21):1593–603.PubMedCrossRef
121.
Waterman RS, Tomchuck SL, Henkle SL, Betancourt AMJ. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE. 2010;5(4):e10088.PubMedPubMedCentralCrossRef
122.
Waterman RS, Henkle SL, Betancourt AMJ. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS ONE. 2012;7(9):e45590.PubMedPubMedCentralCrossRef
123.
Gwendal L. Recent discoveries concerning the tumor-mesenchymal stem cell interactions. BBA Rev Cancer. 2016;1866(2):290–9.
124.
Pan M, Hou L, Zhang J, Zhao D, Hua J, Wang Z, et al. Inhibitory effect and molecular mechanism of mesenchymal stem cells on NSCLC cells. Mol Cell Biochem. 2018;441(1–2):63–76.PubMedCrossRef
125.
Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8(1):122.PubMedPubMedCentralCrossRef
126.
Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int. 2013;2013:732742.PubMedPubMedCentralCrossRef
127.
Hu Y-L, Fu Y-H, Tabata Y, Gao J-Q. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release. 2010;147(2):154–62.PubMedCrossRef
128.
Zhou J, Tan X, Tan Y, Li Q, Ma J, Wang G. Mesenchymal stem cell derived exosomes in cancer progression, metastasis and drug delivery: a comprehensive review. J Cancer. 2018;9(17):3129.PubMedPubMedCentralCrossRef
129.
Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, et al. Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: a clinical study protocol. Medicine. 2018;97:17.CrossRef
130.
Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, et al. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE. 2018;13(5):e0195891.PubMedPubMedCentralCrossRef
131.
Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R, et al. Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study. J Orthop Surg Res. 2017;12(1):190.PubMedPubMedCentralCrossRef
132.
Li GC, Ye QH, Xue YH, Sun HJ, Zhou HJ, Ren N, et al. Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci. 2010;101(12):2546–53.PubMedCrossRef
133.
Zhao W, Ren G, Zhang L, Zhang Z, Liu J, Kuang P, et al. Efficacy of mesenchymal stem cells derived from human adipose tissue in inhibition of hepatocellular carcinoma cells in vitro. Cancer Biother Radiopharm. 2012;27(9):606–13.PubMedCrossRef
134.
Li T, Song B, Du X, Wei Z. Huo TJEjomr. Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study. 2013;18(1):34.
135.
Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008;18(4):500.PubMedCrossRef
136.
Bruno S, Collino F, Deregibus MC, Grange C, Tetta C, Camussi GJ, et al. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2012;22(5):758–71.PubMedCrossRef
137.
Ma B, Jiang H, Jia J, Di L, Song G, Yu J, et al. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clin Transl Oncol. 2012;14(10):764–73.PubMedCrossRef
138.
Abd-Allah SH, Shalaby SM, Amal S, Elkader EA, Hussein S, Emam E, et al. Effect of bone marrow–derived mesenchymal stromal cells on hepatoma. Cytotherapy. 2014;16(9):1197–206.PubMedCrossRef
139.
Seyhoun I, Hajighasemlou S, Muhammadnejad S, Ai J, Nikbakht M, Alizadeh A, et al. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma. J Cell Physiol. 2018;234(6):9495–503.PubMedCrossRef
140.
Hajighasemlou S, Pakzad S, Ai J, Muhammadnejad S, Mirmoghtadaei M, Hosseinzadeh F, et al. Characterization and Validation of hepatocellular carcinoma (HCC) xenograft tumor as a suitable liver cancer model for preclinical mesenchymal stem cell studies. APJCP. 2018;19(6):1627.PubMedPubMedCentral
141.
Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, Bröker ME, Hoogduijn MJ, Ijzermans JN, et al. Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis. 2013;34(10):2330–40.PubMedPubMedCentralCrossRef
142.
Yan XL, Jia YL, Chen L, Zeng Q, Zhou JN, Fu CJ, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology. 2013;57(6):2274–86.PubMedCrossRef
143.
Gong P, Wang Y, Wang Y, Jin S, Luo H, Zhang J, et al. Effect of bone marrow mesenchymal stem cells on hepatocellular carcinoma in microcirculation. Tumor Biol. 2013;34(4):2161–8.CrossRef
144.
Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, et al. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS ONE. 2012;7(8):e43272.PubMedPubMedCentralCrossRef
145.
Bhattacharya SD, Mi Z, Talbot LJ, Guo H, Kuo PCJS. Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers. Surgery. 2012;152(3):449–54.PubMedCrossRef
146.
Liu C, Liu Y, Xu X, Guo X, Sun G, Ma X. Mesenchymal stem cells enhance the metastasis of 3D-cultured hepatocellular carcinoma cells. BMC Cancer. 2016;16(1):566.PubMedPubMedCentralCrossRef
Metadata
Title
Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways
Authors
Jafar Ai
Neda Ketabchi
Javad Verdi
Nematollah Gheibi
Hossein Khadem Haghighian
Maria Kavianpour
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-1038-0

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Overexpression of lncRNA PIK3CD-AS1 promotes expression of LATS1 by competitive binding with microRNA-566 to inhibit the growth, invasion and metastasis of hepatocellular carcinoma cells

Primary research

Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA

Primary research

p62 acts as an oncogene and is targeted by miR-124-3p in glioma

Primary research

Histone methyltransferase SUV39H2 regulates cell growth and chemosensitivity in glioma via regulation of hedgehog signaling

Review

New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin

Primary research

Two predictive precision medicine tools for hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits